Skip to main content
Erschienen in: Gastric Cancer 2/2021

06.11.2020 | Original Article

Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis

verfasst von: Chiara Molinari, Gianluca Tedaldi, Francesca Rebuzzi, Paolo Morgagni, Laura Capelli, Sara Ravaioli, Maria Maddalena Tumedei, Emanuela Scarpi, Anna Tomezzoli, Riccardo Bernasconi, Maria Raffaella Ambrosio, Alessia D’Ignazio, Leonardo Solaini, Francesco Limarzi, Giorgio Ercolani, Giovanni Martinelli, Paola Ulivi, Luca Saragoni

Erschienen in: Gastric Cancer | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Early Gastric Cancer (EGC) reaches 25% of the gastric cancers surgically treated in some areas of Northeastern Italy and is usually characterized by a good prognosis. However, among EGCs classified according to Kodama’s criteria, Pen A subgroup is characterized by extensive submucosal invasion, lymph node metastases and worse prognosis, whereas Pen B subgroup by better prognosis. The aim of the study was to characterize the differences between Pen A, Pen B and locally advanced gastric cancer (T3N0) in order to identify biomarkers involved in aggressiveness and clinical outcome.

Methods

We selected 33 Pen A, 34 Pen B and 20 T3N0 tumors and performed immunohistochemistry of mucins, copy number variation analysis of a gene panel, microsatellite instability (MSI), TP53 mutation and loss of heterozygosity (LOH) analyses.

Results

Pen A subgroup was characterized by MUC6 overexpression (p = 0.021). Otherwise, the Pen B subgroup was significantly associated with the amplification of GATA6 gene (p = 0.002). The higher percentage of MSI tumors was observed in T3N0 group (p = 0.002), but no significant differences between EGC types were found. Finally, TP53 gene analysis showed that 32.8% of Pen tumors have a mutation in exons 5–8 and 50.0% presented LOH. Co-occurrence of TP53 mutation and LOH mainly characterized Pen A tumors (p = 0.022).

Conclusions

Our analyses revealed that clinico-pathological parameters, microsatellite status and frequency of TP53 mutations do not seem to distinguish Pen subgroups. Conversely, the amplification of GATA6 was associated with Pen B, as well as the overexpression of MUC6 and the TP53mut/LOH significantly characterized Pen A.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMed Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.PubMed
2.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma English edition. Gastric Cancer. 2011;14:101–12. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma English edition. Gastric Cancer. 2011;14:101–12.
3.
Zurück zum Zitat Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet (London, England). 2016;388:2654–64. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet (London, England). 2016;388:2654–64.
4.
Zurück zum Zitat Saragoni L, Gaudio M, Vio A, Folli S, Nanni O, Saragoni A. Early gastric cancer in the province of Forlì: follow-up of 337 patients in a high risk region for gastric cancer. Oncol Rep. 1998;5:945–8.PubMed Saragoni L, Gaudio M, Vio A, Folli S, Nanni O, Saragoni A. Early gastric cancer in the province of Forlì: follow-up of 337 patients in a high risk region for gastric cancer. Oncol Rep. 1998;5:945–8.PubMed
5.
Zurück zum Zitat Sano T, Sasako M, Kinoshita T, Maruyama K. Recurrence of early gastric cancer. Follow-up of 1475 patients and review of the Japanese literature. Cancer. 1993;72:3174–8.PubMed Sano T, Sasako M, Kinoshita T, Maruyama K. Recurrence of early gastric cancer. Follow-up of 1475 patients and review of the Japanese literature. Cancer. 1993;72:3174–8.PubMed
6.
Zurück zum Zitat Bollschweiler E, Berlth F, Baltin C, Mönig S, Hölscher AH. Treatment of early gastric cancer in the Western World. World J Gastroenterol. 2014;20:5672–8.PubMedPubMedCentral Bollschweiler E, Berlth F, Baltin C, Mönig S, Hölscher AH. Treatment of early gastric cancer in the Western World. World J Gastroenterol. 2014;20:5672–8.PubMedPubMedCentral
7.
Zurück zum Zitat Sano T, Katai H, Sasako M, Maruyama K. The management of early gastric cancer. Surg Oncol. 2000;9:17–22.PubMed Sano T, Katai H, Sasako M, Maruyama K. The management of early gastric cancer. Surg Oncol. 2000;9:17–22.PubMed
8.
Zurück zum Zitat Abe S, Yoshimura H, Nagaoka S, Monden N, Kinugasa S, Nagasue N, et al. Long-term results of operation for carcinoma of the stomach in T1/T2 stages: critical evaluation of the concept of early carcinoma of the stomach. J Am Coll Surg. 1995;181:389–96.PubMed Abe S, Yoshimura H, Nagaoka S, Monden N, Kinugasa S, Nagasue N, et al. Long-term results of operation for carcinoma of the stomach in T1/T2 stages: critical evaluation of the concept of early carcinoma of the stomach. J Am Coll Surg. 1995;181:389–96.PubMed
9.
Zurück zum Zitat Sano T, Kobori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg. 1992;79:241–4.PubMed Sano T, Kobori O, Muto T. Lymph node metastasis from early gastric cancer: endoscopic resection of tumour. Br J Surg. 1992;79:241–4.PubMed
10.
Zurück zum Zitat Folli S, Dente M, Dell’Amore D, Gaudio M, Nanni O, Saragoni L, et al. Early gastric cancer: prognostic factors in 223 patients. Br J Surg. 1995;82:952–6.PubMed Folli S, Dente M, Dell’Amore D, Gaudio M, Nanni O, Saragoni L, et al. Early gastric cancer: prognostic factors in 223 patients. Br J Surg. 1995;82:952–6.PubMed
11.
Zurück zum Zitat Saragoni L, Gaudio M, Morgagni P, Folli S, Vio A, Scarpi E, et al. The role of growth patterns, according to Kodama’s classification, and lymph node status, as important prognostic factors in early gastric cancer: analysis of 412 cases. Gastric Cancer. 2000;3:134–40.PubMed Saragoni L, Gaudio M, Morgagni P, Folli S, Vio A, Scarpi E, et al. The role of growth patterns, according to Kodama’s classification, and lymph node status, as important prognostic factors in early gastric cancer: analysis of 412 cases. Gastric Cancer. 2000;3:134–40.PubMed
12.
Zurück zum Zitat Jung DH, Huh CW, Kim J-H, Hong JH, Park JC, Lee YC, et al. Risk-Stratification model based on lymph node metastasis after noncurative endoscopic resection for early gastric cancer. Ann Surg Oncol. 2017;24:1643–9.PubMed Jung DH, Huh CW, Kim J-H, Hong JH, Park JC, Lee YC, et al. Risk-Stratification model based on lymph node metastasis after noncurative endoscopic resection for early gastric cancer. Ann Surg Oncol. 2017;24:1643–9.PubMed
13.
Zurück zum Zitat Kodama Y, Inokuchi K, Soejima K, Matsusaka T, Okamura T. Growth patterns and prognosis in early gastric carcinoma. Superficially spreading and penetrating growth types. Cancer. 1983;51:320–6.PubMed Kodama Y, Inokuchi K, Soejima K, Matsusaka T, Okamura T. Growth patterns and prognosis in early gastric carcinoma. Superficially spreading and penetrating growth types. Cancer. 1983;51:320–6.PubMed
14.
Zurück zum Zitat Saragoni L, Morgagni P, Gardini A, Marfisi C, Vittimberga G, Garcea D, et al. Early gastric cancer: diagnosis, staging, and clinical impact. Evaluation of 530 patients. New elements for an updated definition and classification. Gastric Cancer. 2013;16:549–54.PubMed Saragoni L, Morgagni P, Gardini A, Marfisi C, Vittimberga G, Garcea D, et al. Early gastric cancer: diagnosis, staging, and clinical impact. Evaluation of 530 patients. New elements for an updated definition and classification. Gastric Cancer. 2013;16:549–54.PubMed
15.
Zurück zum Zitat Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med. 2015;12:355–61.PubMedPubMedCentral Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med. 2015;12:355–61.PubMedPubMedCentral
16.
Zurück zum Zitat Saragoni L, Scarpi E, Ravaioli A, Morgagni P, Roviello F, Vindigni C, et al. Early gastric cancer: clinical behavior and treatment options. Results of an Italian multicenter study on behalf of the Italian Gastric Cancer Research Group (GIRCG). Oncologist. 2018;23:852–8.PubMedPubMedCentral Saragoni L, Scarpi E, Ravaioli A, Morgagni P, Roviello F, Vindigni C, et al. Early gastric cancer: clinical behavior and treatment options. Results of an Italian multicenter study on behalf of the Italian Gastric Cancer Research Group (GIRCG). Oncologist. 2018;23:852–8.PubMedPubMedCentral
17.
Zurück zum Zitat Morgagni P, Solaini L, Saragoni L, Bencivenga M, Fumagalli Romario U, Graziosi L, et al. An aggressive early gastric cancer: Kodama’s PenA type. Eur J Surg Oncol. 2018;44:1186–90.PubMed Morgagni P, Solaini L, Saragoni L, Bencivenga M, Fumagalli Romario U, Graziosi L, et al. An aggressive early gastric cancer: Kodama’s PenA type. Eur J Surg Oncol. 2018;44:1186–90.PubMed
18.
Zurück zum Zitat Inokuchi K, Kodama Y, Sasaki O, Kamegawa T, Okamura T. Differentiation of growth patterns of early gastric carcinoma determined by cytophotometric DNA analysis. Cancer. 1983;51:1138–41.PubMed Inokuchi K, Kodama Y, Sasaki O, Kamegawa T, Okamura T. Differentiation of growth patterns of early gastric carcinoma determined by cytophotometric DNA analysis. Cancer. 1983;51:1138–41.PubMed
19.
Zurück zum Zitat Chen D, Chen G, Jiang W, Fu M, Liu W, Sui J, et al. Association of the collagen signature in the tumor microenvironment with lymph node metastasis in early gastric cancer. JAMA Surg. 2019;154:e185249.PubMedPubMedCentral Chen D, Chen G, Jiang W, Fu M, Liu W, Sui J, et al. Association of the collagen signature in the tumor microenvironment with lymph node metastasis in early gastric cancer. JAMA Surg. 2019;154:e185249.PubMedPubMedCentral
20.
Zurück zum Zitat Datta J, Da Silva EM, Kandoth C, Song T, Russo AE, Hernandez JM, et al. Poor survival after resection of early gastric cancer: extremes of survivorship analysis reveal distinct genomic profile. Br J Surg. 2020;107:14–9.PubMed Datta J, Da Silva EM, Kandoth C, Song T, Russo AE, Hernandez JM, et al. Poor survival after resection of early gastric cancer: extremes of survivorship analysis reveal distinct genomic profile. Br J Surg. 2020;107:14–9.PubMed
21.
Zurück zum Zitat Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965;64:31–49.PubMed
22.
Zurück zum Zitat Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.PubMed Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004;96:261–8.PubMed
23.
Zurück zum Zitat Bunyan DJ, Eccles DM, Sillibourne J, Wilkins E, Thomas NS, Shea-Simonds J, et al. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer. 2004;91:1155–9.PubMedPubMedCentral Bunyan DJ, Eccles DM, Sillibourne J, Wilkins E, Thomas NS, Shea-Simonds J, et al. Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification. Br J Cancer. 2004;91:1155–9.PubMedPubMedCentral
24.
Zurück zum Zitat den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS Recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37:564–9. den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS Recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016;37:564–9.
25.
Zurück zum Zitat Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–91.PubMedPubMedCentral Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–91.PubMedPubMedCentral
26.
Zurück zum Zitat Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.PubMedPubMedCentral Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.PubMedPubMedCentral
27.
Zurück zum Zitat Saeki H, Kitao H, Yoshinaga K, Nakanoko T, Kubo N, Kakeji Y, et al. Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clin Cancer Res. 2011;17:1731–40.PubMed Saeki H, Kitao H, Yoshinaga K, Nakanoko T, Kubo N, Kakeji Y, et al. Copy-neutral loss of heterozygosity at the p53 locus in carcinogenesis of esophageal squamous cell carcinomas associated with p53 mutations. Clin Cancer Res. 2011;17:1731–40.PubMed
28.
Zurück zum Zitat Oki E, Zhao Y, Yoshida R, Egashira A, Ohgaki K, Morita M, et al. The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract. Digestion. 2009;79(Suppl 1):33–9.PubMed Oki E, Zhao Y, Yoshida R, Egashira A, Ohgaki K, Morita M, et al. The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract. Digestion. 2009;79(Suppl 1):33–9.PubMed
30.
Zurück zum Zitat Ho SB, Shekels LL, Toribara NW, Kim YS, Lyftogt C, Cherwitz DL, et al. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res. 1995;55:2681–90.PubMed Ho SB, Shekels LL, Toribara NW, Kim YS, Lyftogt C, Cherwitz DL, et al. Mucin gene expression in normal, preneoplastic, and neoplastic human gastric epithelium. Cancer Res. 1995;55:2681–90.PubMed
32.
Zurück zum Zitat Bartman AE, Buisine MP, Aubert JP, Niehans GA, Toribara NW, Kim YS, et al. The MUC6 secretory mucin gene is expressed in a wide variety of epithelial tissues. J Pathol. 1998;186:398–405.PubMed Bartman AE, Buisine MP, Aubert JP, Niehans GA, Toribara NW, Kim YS, et al. The MUC6 secretory mucin gene is expressed in a wide variety of epithelial tissues. J Pathol. 1998;186:398–405.PubMed
33.
Zurück zum Zitat Saito A, Shimoda T, Nakanishi Y, Ochiai A, Toda G. Histologic heterogeneity and mucin phenotypic expression in early gastric cancer. Pathol Int. 2001;51:165–71.PubMed Saito A, Shimoda T, Nakanishi Y, Ochiai A, Toda G. Histologic heterogeneity and mucin phenotypic expression in early gastric cancer. Pathol Int. 2001;51:165–71.PubMed
34.
Zurück zum Zitat Cavalcanti E, De Michele F, Lantone G, Panarese A, Caruso ML. Mucin phenotype of differentiated early gastric cancer: an immunohistochemistry study supporting therapeutic decision making. Cancer Manag Res. 2019;11:5047–54.PubMedPubMedCentral Cavalcanti E, De Michele F, Lantone G, Panarese A, Caruso ML. Mucin phenotype of differentiated early gastric cancer: an immunohistochemistry study supporting therapeutic decision making. Cancer Manag Res. 2019;11:5047–54.PubMedPubMedCentral
35.
Zurück zum Zitat Kocer B, Soran A, Kiyak G, Erdogan S, Eroglu A, Bozkurt B, et al. Prognostic significance of mucin expression in gastric carcinoma. Dig Dis Sci. 2004;49:954–64.PubMed Kocer B, Soran A, Kiyak G, Erdogan S, Eroglu A, Bozkurt B, et al. Prognostic significance of mucin expression in gastric carcinoma. Dig Dis Sci. 2004;49:954–64.PubMed
36.
Zurück zum Zitat Koseki K, Takizawa T, Koike M, Ito M, Nihei Z, Sugihara K. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. Cancer. 2000;89:724–32.PubMed Koseki K, Takizawa T, Koike M, Ito M, Nihei Z, Sugihara K. Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. Cancer. 2000;89:724–32.PubMed
37.
Zurück zum Zitat Kerckhoffs KGP, Liu DHW, Saragoni L, van der Post RS, Langer R, Bencivenga M, et al. Mucin expression in gastric- and gastro-oesophageal signet-ring cell cancer: results from a comprehensive literature review and a large cohort study of Caucasian and Asian gastric cancer. Gastric Cancer. 2020;23:765–79.PubMedPubMedCentral Kerckhoffs KGP, Liu DHW, Saragoni L, van der Post RS, Langer R, Bencivenga M, et al. Mucin expression in gastric- and gastro-oesophageal signet-ring cell cancer: results from a comprehensive literature review and a large cohort study of Caucasian and Asian gastric cancer. Gastric Cancer. 2020;23:765–79.PubMedPubMedCentral
38.
Zurück zum Zitat Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.
39.
Zurück zum Zitat Polom K, Marrelli D, Pascale V, Ferrara F, Voglino C, Marini M, et al. The pattern of lymph node metastases in microsatellite unstable gastric cancer. Eur J Surg Oncol. 2017;43:2341–8.PubMed Polom K, Marrelli D, Pascale V, Ferrara F, Voglino C, Marini M, et al. The pattern of lymph node metastases in microsatellite unstable gastric cancer. Eur J Surg Oncol. 2017;43:2341–8.PubMed
40.
Zurück zum Zitat Mizuguchi A, Takai A, Shimizu T, Matsumoto T, Kumagai K, Miyamoto S, et al. Genetic features of multicentric/multifocal intramucosal gastric carcinoma. Int J cancer. 2018;143:1923–34.PubMed Mizuguchi A, Takai A, Shimizu T, Matsumoto T, Kumagai K, Miyamoto S, et al. Genetic features of multicentric/multifocal intramucosal gastric carcinoma. Int J cancer. 2018;143:1923–34.PubMed
41.
Zurück zum Zitat Kim DG, An JY, Kim H, Shin S-J, Choi S, Seo WJ, et al. Clinical implications of microsatellite instability in early gastric cancer. J Gastric Cancer. 2019;19:427–37.PubMedPubMedCentral Kim DG, An JY, Kim H, Shin S-J, Choi S, Seo WJ, et al. Clinical implications of microsatellite instability in early gastric cancer. J Gastric Cancer. 2019;19:427–37.PubMedPubMedCentral
42.
Zurück zum Zitat Sugai T, Eizuka M, Arakawa N, Osakabe M, Habano W, Fujita Y, et al. Molecular profiling and comprehensive genome-wide analysis of somatic copy number alterations in gastric intramucosal neoplasias based on microsatellite status. Gastric Cancer. 2018;21:765–75.PubMedPubMedCentral Sugai T, Eizuka M, Arakawa N, Osakabe M, Habano W, Fujita Y, et al. Molecular profiling and comprehensive genome-wide analysis of somatic copy number alterations in gastric intramucosal neoplasias based on microsatellite status. Gastric Cancer. 2018;21:765–75.PubMedPubMedCentral
43.
Zurück zum Zitat Ooi A, Oyama T, Nakamura R, Tajiri R, Ikeda H, Fushida S, et al. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. Hum Pathol. 2017;61:58–67.PubMed Ooi A, Oyama T, Nakamura R, Tajiri R, Ikeda H, Fushida S, et al. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. Hum Pathol. 2017;61:58–67.PubMed
44.
Zurück zum Zitat Tsuji S, Kawasaki Y, Furukawa S, Taniue K, Hayashi T, Okuno M, et al. The miR-363-GATA6-Lgr5 pathway is critical for colorectal tumourigenesis. Nat Commun. 2014;5:3150.PubMed Tsuji S, Kawasaki Y, Furukawa S, Taniue K, Hayashi T, Okuno M, et al. The miR-363-GATA6-Lgr5 pathway is critical for colorectal tumourigenesis. Nat Commun. 2014;5:3150.PubMed
45.
Zurück zum Zitat Zhong Y, Wang Z, Fu B, Pan F, Yachida S, Dhara M, et al. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. PLoS ONE. 2011;6:e22129.PubMedPubMedCentral Zhong Y, Wang Z, Fu B, Pan F, Yachida S, Dhara M, et al. GATA6 activates Wnt signaling in pancreatic cancer by negatively regulating the Wnt antagonist Dickkopf-1. PLoS ONE. 2011;6:e22129.PubMedPubMedCentral
46.
Zurück zum Zitat Martinelli P, Carrillo-de Santa Pau E, Cox T, Sainz B, Dusetti N, Greenhalf W, et al. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut. 2017;66:1665–76.PubMed Martinelli P, Carrillo-de Santa Pau E, Cox T, Sainz B, Dusetti N, Greenhalf W, et al. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut. 2017;66:1665–76.PubMed
47.
Zurück zum Zitat Martinelli P, Madriles F, Cañamero M, Pau ECS, Del PN, Guerra C, et al. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice. Gut. 2016;65:476–86.PubMed Martinelli P, Madriles F, Cañamero M, Pau ECS, Del PN, Guerra C, et al. The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice. Gut. 2016;65:476–86.PubMed
48.
Zurück zum Zitat Sulahian R, Casey F, Shen J, Qian ZR, Shin H, Ogino S, et al. An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene. 2014;33:5637–48.PubMed Sulahian R, Casey F, Shen J, Qian ZR, Shin H, Ogino S, et al. An integrative analysis reveals functional targets of GATA6 transcriptional regulation in gastric cancer. Oncogene. 2014;33:5637–48.PubMed
49.
Zurück zum Zitat Chia N-Y, Deng N, Das K, Huang D, Hu L, Zhu Y, et al. Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. Gut. 2015;64:707–19.PubMed Chia N-Y, Deng N, Das K, Huang D, Hu L, Zhu Y, et al. Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. Gut. 2015;64:707–19.PubMed
50.
Zurück zum Zitat Liu H, Du F, Sun L, Wu Q, Wu J, Tong M, et al. GATA6 suppresses migration and metastasis by regulating the miR-520b/CREB1 axis in gastric cancer. Cell Death Dis. 2019;10:35.PubMedPubMedCentral Liu H, Du F, Sun L, Wu Q, Wu J, Tong M, et al. GATA6 suppresses migration and metastasis by regulating the miR-520b/CREB1 axis in gastric cancer. Cell Death Dis. 2019;10:35.PubMedPubMedCentral
51.
Zurück zum Zitat Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.PubMed Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401–4.PubMed
52.
Zurück zum Zitat Bellini MF, Cadamuro ACT, Succi M, Proença MA, Silva AE. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012;2012:891961.PubMedPubMedCentral Bellini MF, Cadamuro ACT, Succi M, Proença MA, Silva AE. Alterations of the TP53 gene in gastric and esophageal carcinogenesis. J Biomed Biotechnol. 2012;2012:891961.PubMedPubMedCentral
53.
Zurück zum Zitat Sethi NS, Kikuchi O, Duronio GN, Stachler MD, McFarland JM, Ferrer-Luna R, et al. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet. 2020;52:219–30.PubMedPubMedCentral Sethi NS, Kikuchi O, Duronio GN, Stachler MD, McFarland JM, Ferrer-Luna R, et al. Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. Nat Genet. 2020;52:219–30.PubMedPubMedCentral
54.
Zurück zum Zitat Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008.PubMedPubMedCentral Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2:a001008.PubMedPubMedCentral
55.
Zurück zum Zitat Alexandrova EM, Mirza SA, Xu S, Schulz-Heddergott R, Marchenko ND, Moll UM. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo. Cell Death Dis. 2017;8:e2661.PubMedPubMedCentral Alexandrova EM, Mirza SA, Xu S, Schulz-Heddergott R, Marchenko ND, Moll UM. p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo. Cell Death Dis. 2017;8:e2661.PubMedPubMedCentral
Metadaten
Titel
Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis
verfasst von
Chiara Molinari
Gianluca Tedaldi
Francesca Rebuzzi
Paolo Morgagni
Laura Capelli
Sara Ravaioli
Maria Maddalena Tumedei
Emanuela Scarpi
Anna Tomezzoli
Riccardo Bernasconi
Maria Raffaella Ambrosio
Alessia D’Ignazio
Leonardo Solaini
Francesco Limarzi
Giorgio Ercolani
Giovanni Martinelli
Paola Ulivi
Luca Saragoni
Publikationsdatum
06.11.2020
Verlag
Springer Singapore
Erschienen in
Gastric Cancer / Ausgabe 2/2021
Print ISSN: 1436-3291
Elektronische ISSN: 1436-3305
DOI
https://doi.org/10.1007/s10120-020-01135-8

Weitere Artikel der Ausgabe 2/2021

Gastric Cancer 2/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.